Sign in
or
Register
0
Add listing
View all results
No results
News
Events
The industry
arrow_drop_down
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Networking platforms
Newsletter
Association
arrow_drop_down
Mission and services
Members
Academy
Partners
Team
Media
Add listing
Flexyn2a
Product
prev
next
Leave a review
Claim listing
Bookmark
Share
Report
prev
next
Indicaton
Shigella flexneri 2a Infections
Therapeutic indications
Infectious disease
Company
LimmaTech Biologics AG
Table
Partnering status
n/a
You may also be interested in
Debio 4028
Infectious diseases Debio 4028 program leverages the immunomodulatory, pro-apoptotic and virus-reactivating properties of a new generation of potent, orally available Inhibitor of Apoptosis Proteins (IAP) antagonists to cure various chronic infectious diseases. These new molecules are expected to allow the discontinuation of any antiviral treatment and eliminate the risk of clinical relapse, transmission of the infection and long-term complications.
Discovery
Debio 025
GI disorders Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, with a potential in a wide range of therapeutic indications. Alisporivir was first thoroughly investigated for its antiviral properties in hepatitis C and HIV patients and consequently benefits from a large safety and efficacy database. Today, our development efforts are focused on non-viral diseases where cylophilins play a key role in regulating cell death pathways and we strive to generate compelling evidence supporting further clinical investigations in patients with high unmet medical needs.
Discovery
Debio 1561
Infectious diseases Debio 1561 FibroTrap is a unique sample preparation technology for the concentration of bacteria and other microorganisms in blood samples of patients with bloodstream infections (BSI). The technology will enable faster identification and diagnosis of pathogens directly from patient samples and will promote an accelerated selection of more appropriate antibiotics to improve treatment outcomes (antibiotics stewardship).
Phase II started
Cart
×
View all results
No results
Facebook
Twitter
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
VKontakte
Mail
Copy link
This site uses cookies:
Find out more.
Accept